Showing 2271-2280 of 3039 results for "".
- MyEyeDr. Partners with CoFi to Streamline Patient Paymentshttps://modernod.com/news/myeyedr-partners-with-cofi-to-streamline-patient-payments/2482673/MyEyeDr., which has 880 locations across the US, has teamed up with multi-party payment provider CoFi to simplify the payment process for patients requiring both optometry and ophthalmology services. This new partnership, now available in all 29 states where MyEyeDr. o
- EssilorLuxottica Acquires Canadian Med-Tech Start-Up Cellviewhttps://modernod.com/news/essilorluxottica-acquires-canadian-med-tech-start-up-cellview/2482659/EssilorLuxottica has acquired Cellview Imaging, a Canadian start-up specializing in diagnostic via retinal imaging. Financial terms of the deal were not disclosed. Based in Toronto, Cellview designs and manufactures diagnostic imaging instruments. Currently distributed in North Ame
- AEYE Health and Topcon Healthcare Announce Results of Autonomous DR Screening Studyhttps://modernod.com/news/aeye-health-partners-with-topcon-healthcare-announce-results-of-autonomous-dr-screening-technology/2482657/AEYE Health and Topcon Healthcare announced results of a recent study evaluating Topcon’s NW500 non-mydriatic retinal camera and AEYE Diagnostic Screening (AEYE-DS). In the study, the AEYE-DS AI technology, in conjunction with the Topcon
- Study Demonstrates Efficacy of AI in Enabling Home OCT Monitoringhttps://modernod.com/news/study-demonstrates-efficacy-of-ai-in-enabling-home-oct-monitoring/2482641/Notal Vision announced the publication of pivotal study results evaluating the performance of its artificial intelligence (AI) algorithm designed to estimate key biomarkers in wet age-
- Dry Eye Institute Launches 'DEI On Demand' and Kicks Off Inaugural Road Eventhttps://modernod.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/The Dry Eye Institute (DEI), an educational program for optometrists and ophthalmologists specializing in advanced dry eye care, has announced that for the first time, the institute’s curriculum is now available online through 'DEI On Demand.' DEI also announced that
- ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901; DSMB Approval to Advance Dose Escalation in Phase 1b RP Trialhttps://modernod.com/news/vigeneron-announces-fda-rare-pediatric-disease-designation-for-vg901-dsmb-approval-to-advance-dose-escalation-in-phase-1b-rp-trial/2482601/ViGeneron announced two important milestones for its novel gene therapy candidate VG901 to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The FDA granted Rare Pediatric Disease Designation (RPD
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- VisionGift Announces the Retirement of Longtime Medical Director, Mark Terry, MDhttps://modernod.com/news/visiongift-announces-the-retirement-of-longtime-medical-director-mark-terry-md/2482595/VisionGift, a nonprofit dedicated ot ocular donation and corneal transplantation, announced the retirement of its medical director Mark Terry, MD, after 34 years of dedicated service to the field of eye banking. Succeeding him in this role will be Winston Chamberlain, MD, PhD, and
- Prevent Blindness Provides Free Glaucoma Resources to Patients, Care Partners, and Professionalshttps://modernod.com/news/prevent-blindness-provides-free-glaucoma-resources-to-patients-care-partners-and-professionals/2482593/As part of January’s National Glaucoma Awareness Month, the non-profit Prevent Blindness is offering free educational resources to patients, care partners, and professionals. The resources include downloadable
- Opus Genetics Receives FDA Agreement Under SPA for Phase 3 Trial of APX3330 in DRhttps://modernod.com/news/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy/2482587/Opus Genetics announced it has reached agreement with the FDA on a Special Protocol Assessment (SPA) for a phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).